<!DOCTYPE html>
<html lang="en" dir="ltr"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    
    <meta name="MobileOptimized" content="width">
    <meta name="HandheldFriendly" content="true">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>U-PGx Demo PGx Report</title>
    <style media="all">
      @import url("style.css");
    </style>

  </head>
  <body>
    
  <div data-segment-key="summary">

<div align="center"><img src="upgx_logo.jpg" width="100%"></div>
<p class ="disclaimer">This site is provided for demonstration purposes only and comes without any warranty. 
For more information on the U-PGx project, please visit <a href="http://www.upgx.eu" target="_blank">http://www.upgx.eu</a>. For more information on the safety-code system, 
please visit <a href="http://www.safety-code.org" target="_blank">http://www.safety-code.org</a>.</p>
<h2>Patient information</h2>
<ul>
<li>Name: Jane Doe</li>
<li>Date of birth (DD.MM.YYYY): 01.02.1934</li>
<li>Patient study ID: 0000001</li>
</ul>
<h2>Report information</h2>
<ul>
<li>Order date (DD.MM.YYYY): 10.06.2017</li>
<li>Ordered by: Dr. X</li>
<li>Report date (DD.MM.YYYY): 15.06.2017</li> 
<li>Laboratory contact:</li>
</ul>
<h2>Drugs with therapeutic recommendations (in alphabetical order)</h2>
<ul>
<li><a href="#amitriptyline">Amitriptyline</a></li>
<li><a href="#azathioprine">Azathioprine</a></li>
<li><a href="#clomipramine">Clomipramine</a></li>
<li><a href="#clopidogrel">Clopidogrel</a></li>
<li><a href="#codeine">Codeine</a></li>
<li><a href="#doxepin">Doxepin</a></li>
<li><a href="#haloperidol">Haloperidol</a></li>
<li><a href="#imipramine">Imipramine</a></li>
<li><a href="#mercaptopurine">Mercaptopurine</a></li>
<li><a href="#metoprolol">Metoprolol</a></li>
<li><a href="#nortriptyline">Nortriptyline</a></li>
<li><a href="#propafenone">Propafenone</a></li>
<li><a href="#sertraline">Sertraline</a></li>
<li><a href="#thioguanine">Thioguanine</a></li>
<li><a href="#tramadol">Tramadol</a></li>
<li><a href="#venlafaxine">Venlafaxine</a></li>
</ul>

<h2>Pharmacogenomic variants affecting drug response (see below for detailed results)</h2>
<table>
<thead><tr>
<th>Gene</th>
<th>Phenotype / status</th>
</tr></thead>
<tbody>
<tr>
<td><em>CYP2C19</em></td>
<td><p>Poor metabolizer</p></td>
</tr>
<tr>
<td><em>CYP2D6</em></td>
<td><p>Ultrarapid metabolizer</p></td>
</tr>
<tr>
<td><em>TPMT</em></td>
<td><p>Poor metabolizer</p></td>
</tr>

</tbody>
</table>
</div>
  <div data-segment-key="recommendations">


<h2>RECOMMENDATIONS (in alphabetical order)</h2>
<details id="amitriptyline" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="amitriptyline" aria-expanded="false" aria-pressed="false" class="heading-5">Amitriptyline</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause a decrease in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and increased plasma concentrations of the active metabolites E-10-OH-amitriptyline and E-10-OH-nortriptyline.
</p><br>
<p>Recommendation:</p>

Choose an alternative if possible
Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.
If an alternative is not an option: increase the dose to 1.25 times the standard dose, monitor the plasma concentrations and be alert to potential therapy failure due to decreased amitriptyline plus nortriptyline plasma concentrations and to increased plasma concentrations of the potentially cardiotoxic, active hydroxy metabolites.
  
</details>

<details id="azathioprine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="azathioprine" aria-expanded="false" aria-pressed="false" class="heading-5">Azathioprine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>TPMT</em> Poor metabolizer</p>

<p>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.
</p>
<p>Recommendation:</p>

<ol><li>Choose an alternative or start with 10% of the standard dose.
Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.
The frequency of monitoring should be increased.</li>
<li>If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur
</li></ol></details>

<details id="clomipramine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="clomipramine" aria-expanded="false" aria-pressed="false" class="heading-5">Clomipramine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6. This may cause increased plasma concentrations of clomipramine and the active metabolite and decreased concentrations of the potentially cardiotoxic hydroxy metabolites.
</p><br>
<p>Recommendation:</p>

<ul><li>
Indication DEPRESSION:
<ol><li>
decrease the dose to 50% of the standard dose</li>
<li>monitor the plasma concentrations of clomipramine and N-desmethylclomipramine</li></ol>
<li>Indication ANXIETY DISORDERS:
<ol><li>choose an alternative
Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</li>
<li>if an alternative is not an option and side effects occur:</li>
<ol><li>
reduce the dose by 50%</li>
<li>
monitor the plasma concentrations of clomipramine and N-desmethylclomipramine
It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear while the effectiveness is retained. Clomipramine and N-desmethylclomipramine both contribute to the side effects. Only clomipramine contributes to the effectiveness.
</li></ol></li></ul></details>

<details id="clopidogrel" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="clopidogrel" aria-expanded="false" aria-pressed="false" class="heading-5">Clopidogrel</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2C19</em> Poor metabolizer</p>

<p>Genetic variation reduces activation of clopidogrel. This increases the risk of serious cardiovascular events in patients undergoing balloon angioplasty or stent placement (percutaneous coronary intervention). No negative clinical consequences have been proved in other patients.
</p><br>
<p>Recommendation:</p>

<ul><li>PERCUTANEOUS CORONARY INTERVENTION:
<ol><li>choose an alternative
Prasugrel and ticagrelor are not metabolised by CYP2C19 (or to a lesser extent).</li></ol></li>
<li>OTHER INDICATIONS:
<ol><li>determine the level of inhibition of platelet aggregation by clopidogrel</li>
<li>consider an alternative in poor responders
Prasugrel and ticagrelor are not metabolised by CYP2C19 (or to a lesser extent).</li></ol></ul></details>

<details id="codeine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="codeine" aria-expanded="false" aria-pressed="false" class="heading-5">Codeine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2CD6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism increases the conversion of codeine to morphine. This can result in an increase in side effects. Death has occurred in children.
</p><br>
<p>Recommendation:</p>
<br>
Codeine is contra-indicated for CYP2D6 UM.
<ol><li>
if possible, select an alternative
For PAIN: do not select tramadol, as this is also metabolised by CYP2D6.
Oyxcodone is also metabolised by CYP2D6, but generally the dose can be titrated so that adequate analgesia is achieved without side effects.</details>
</li></ol>
<details id="doxepin" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="doxepin" aria-expanded="false" aria-pressed="false" class="heading-5">Doxepin</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased plasma concentrations of doxepin and nordoxepin and an increase in the plasma concentration of the hydroxy metabolites.
</p><br>
<p>Recommendation:</p>
<ul><li>
choose an alternative
Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.
</li>
<li>if an alternative is not an option: increase the dose to 200% of the standard dose and monitor the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose</details>
</li></ul></details>

<details id="haloperidol" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="haloperidol" aria-expanded="false" aria-pressed="false" class="heading-5">Haloperidol</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased plasma concentrations of haloperidol and the active metabolite reduced haloperidol.
</p><br>

<p>Recommendation:</p>
It is not possible to offer substantiated advice for dose adjustment due to the limited amount of available literature.

Advise the prescriber to:
<ol><li>be alert to possible reduced plasma concentrations of haloperidol and reduced haloperidol and increase the dose based on results of therapeutic drug monitoring,
</li><li>or prescribe an alternative according to the current guidelines.
Anti-psychotics that are not metabolised via CYP2D6 - or to a much lesser extent - include, for example, flupentixol, fluphenazine, quetiapine, olanzapine or clozapine.
</li></ol>
</details>

<details id="imipramine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="imipramine" aria-expanded="false" aria-pressed="false" class="heading-5">Imipramine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased plasma concentrations of imipramine and desipramine and an increase in the plasma concentration of the hydroxy metabolites.
</p>
<br>

<p>Recommendation:</p>

<ol><li>choose an alternative
Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.
</li><li>if an alternative is not an option: increase the dose to 170% of the standard dose and monitor the plasma concentrations of imipramine and desipramine in order to set the maintenance dose
</li></ol></details>

<details id="mercaptopurine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="mercaptopurine" aria-expanded="false" aria-pressed="false" class="heading-5">Mercaptopurine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>TPMT</em> Poor metabolizer</p>

<p>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.
</p>
<p>Recommendation:</p>

<ol><li>Choose an alternative or start with 10% of the standard dose.
Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.
The frequency of monitoring should be increased.</li>
<li>If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur
</li></ol></details>

<details id="metoprolol" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="metoprolol" aria-expanded="false" aria-pressed="false" class="heading-5">Metoprolol</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate.
</p><br>

<p>Recommendation:</p>

<ol><li>use the maximum dose for the relevant indication as a target dose</li>
<li>if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative
Possible alternatives include:<ul>
<li>
HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6.
</li><li>OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</li></li></ol></details>

<details id="nortriptyline" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="nortriptyline" aria-expanded="false" aria-pressed="false" class="heading-5">Nortriptyline</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause a decrease in the plasma concentration of nortriptyline and an increase in the plasma concentration of the active metabolite E-10-OH-nortriptyline.
</p>
<br>
<p>Recommendation:</p>

<ol><li>choose an alternative
Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</li>
<li>If an alternative is not an option:
<ul><li>
increase the dose to 160% of the standard dose and monitor the plasma concentration of nortriptyline
</li><li>be alert to an expected increase in the plasma concentration of the possibly cardiotoxic, active metabolite E-10-hydroxynortriptyline
</li></ul></li></ol>
</details>

<details id="propafenone" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="propafenone" aria-expanded="false" aria-pressed="false" class="heading-5">Propafenone</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy.
</p><br>

<p>Recommendation:</p>

<p>It is not possible to poffer adequately substantiated recommendations for dose adjustment based on the literature.
</p>
<ol><li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.
</li><li>Or choose an alternative</li>
<li>Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.
</li></ol></details>

<details id="sertraline" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="sertraline" aria-expanded="false" aria-pressed="false" class="heading-5">Sertraline</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2C19</em> Poor metabolizer</p>

<p>The gene variation leads to increased plasma concentrations of sertraline and the active metabolite desmethylsertraline. This increases the risk of side effects.
</p>
<br>
<p>Recommendation:</p>
<ol><li>
Do not give doses exceeding 50 mg/day</li>
<li>Guide the dose by response and side effects and/or sertraline plus desmethylsertraline plasma concentrations.</li></ol></details>

<details id="thioguanine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="thioguanine" aria-expanded="false" aria-pressed="false" class="heading-5">Thioguanine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>TPMT</em> Poor metabolizer</p>

<p>Genetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.
</p><br>
<p>Recommendation:</p>

<ol><li>Choose an alternative or start with 6-7% of the standard dose</li>
Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.
The frequency of monitoring should be increased.
<li>If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore  throat in combination with fever, regular nosebleeds and tendency to bruising) develop
</li></ol></details>

<details id="tramadol" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="tramadol" aria-expanded="false" aria-pressed="false" class="heading-5">Tramadol</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism reduces the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in side effects.
</p><br>
<p>Recommendation:</p>

<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.
</p>
<ol><li>
decrease the dose to 20-40% of the standard dose</li>
<li>if a dose reduction does not have the desired effect: select an alternative
Do not choose codeine, as it is contra-indicated for CYP2D6 UM.
Oyxcodone is also metabolised by CYP2D6, but generally the dose can be titrated so that adequate analgesia is achieved without side effects.
</li>
<li>if an alternative is not selected: advise the patient to contact their doctor in the event of side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).
</li></ol></details>

<details id="venlafaxine" class="js-form-wrapper form-wrapper">
  <summary role="button" aria-controls="venlafaxine" aria-expanded="false" aria-pressed="false" class="heading-5">Venlafaxine</summary>
  
  <h6>
Common trade names:
</h6>

<p>Phenotype / Variant: <em>CYP2D6</em> Ultrarapid metabolizer</p>

<p>The genetic polymorphism leads to increased metabolic capacity of CYP2D6. This can cause a decrease in the plasma concentration of venlafaxine and an increase in the plasma concentration of the active metabolite O-desmethylvenlafaxine.
</p><br>

<p>Recommendation:</p>
<ol><li>
be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O-desmethylvenlafaxine
</li>
<li>if necessary, increase the dose to 150% of the standard dose</li>
<li>if dose adjustment based on therapeutic drug monitoring is not possible, an alternative should be selected</li>
<li>Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</li>
</ol>
</details>

</div>
  <div data-segment-key="appendix">

<div class="hidden"><h2>Detailed genotype / phenotype results</h2></div>
<details class="js-form-wrapper form-wrapper">
  <summary role="button" aria-expanded="false" aria-pressed="false" class="heading-2">Detailed genotype / phenotype results</summary>
  
  
<table>
<thead><tr>
<th>Gene</th>
<th>Genotype</th>
<th>Phenotype / status</th>
</tr></thead>
<tbody>
<tr>
<td><em>CYP2B6</em></td>
<td>wildtype/wildtype</td>
<td><p>Extensive metabolizer</p></td>
</tr>
<tr>
<td><em>CYP2C19</em></td>
<td>*2/*3</td>
<td><p>Poor metabolizer</p></td>
</tr>
<tr>
<td><em>CYP2C9</em></td>
<td>wildtype/wildtype</td>
<td><p>*1/*1</p></td>
</tr>
<tr>
<td><em>CYP2D6</em></td>
<td>*1/*1xN</td>
<td><p>Ultrarapid metabolizer</p></td>
</tr>
<tr>
<td><em>CYP3A5</em></td>
<td>wildtype/wildtype</td>
<td><p>Extensive metabolizer</p></td>
</tr>
<tr>
<td><em>DPYD</em></td>
<td>wildtype/wildtype</td>
<td><p>Gene activity score 1</p></td>
</tr>
<tr>
<td><em>F5</em></td>
<td>wildtype/wildtype</td>
<td><p>Wildtype</p></td>
</tr>
<tr>
<td><em>HLA-A3101</em></td>
<td>wildtype/wildtype</td>
<td><p>*3101-negative</p></td>
</tr>
<tr>
<td><em>HLA-B5701</em></td>
<td>wildtype/wildtype</td>
<td><p>*5701-negative</p></td>
</tr>
<tr>
<td><em>HLA-B1502</em></td>
<td>wildtype/wildtype</td>
<td><p>*1502-negative</p></td>
</tr>
<tr>
<td><em>SLCO1B1</em></td>
<td>wildtype/wildtype</td>
<td><p>Normal function</p></td>
</tr>
<tr>
<td><em>TPMT</em></td>
<td>*2/*3B</td>
<td><p>Poor metabolizer</p></td>
</tr>
<tr>
<td><em>UGT1A1</em></td>
<td>wildtype/wildtype</td>
<td><p>Extensive metabolizer</p></td>
</tr>
<tr>
<td><em>VKORC1</em></td>
<td>wildtype/wildtype</td>
<td><p>Wildtype</p></td>
</tr>
</tbody>
</table>
  
</details>
<div class="hidden"><h2>Overview of drug substances, relevant phenotypes and availability of recommendations</h2></div>
<details class="js-form-wrapper form-wrapper">
  <summary role="button" aria-expanded="false" aria-pressed="false" class="heading-2">Overview of drug substances, relevant phenotypes and availability of recommendations</summary>
  
  
<table>
<thead><tr>
<th>Drug substance</th>
<th>Relevant phenotype(s) / variant(s)</th>
<th>Recommendation shown in this report? </th>
<th>Reason</th>
</tr></thead>
<tbody>
<tr>
<td>Abacavir</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acenocoumarol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>No</td>
<td>No action recommended according to guideline</td>
</tr>
<tr>
<td>Atenolol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atomoxetine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>TPMT Poor metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Bisoprolol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capecitabine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carvedilol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citalopram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clomipramine</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Clonidine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clopidrogrel</td>
<td>CYP2C19 Poor metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Clozapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Dexmethylphenidate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disopyramide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxepin</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Duloxetine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eliglustat</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escitalopram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esomeprazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flecainide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flucloxacillin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorouracil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fflupentixol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluvastatin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gefitinib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glibenclamide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gliclazide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glimepiride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Imipramine</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Irinotecan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinidine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lansoprazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td>TPMT Poor metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoprolol</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moclobemide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Oestrogen containing contraceptives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olanzapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omeprazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pantoprazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>No</td>
<td>No action recommended according to guideline</td>
</tr>
<tr>
<td>Phenprocoumon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pimozide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prasugrel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propafenone</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Quetiapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabeprazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risperidone</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>No</td>
<td>No action recommended according to guideline</td>
</tr>
<tr>
<td>Sertraline</td>
<td>CYP2C19 Poor metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Simvastatin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sotalol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tacrolimus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>No</td>
<td>No action recommended according to guideline</td>
</tr>
<tr>
<td>Tegafur</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ticagrelor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tioguanine</td>
<td>TPMT Poor metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Tolbutamide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>CYP2D6 Ultrarapid metabolizer</td>
<td>Yes</td>
<td>Therapy modification recommended according to guideline</td>
</tr>
<tr>
<td>Voriconazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zuclopenthixol</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
  
</details>
<div class="hidden"><h2>Disclaimer</h2></div>
<details class="js-form-wrapper form-wrapper">
  <summary role="button" aria-expanded="false" aria-pressed="false" class="heading-2">Disclaimer</summary>
  
  
<h3>General information</h3>
<p>This pharmacogenomic test report was issued within the scope of the PREPARE (PREemptive Pharmacogenomic testing for Preventing Adverse drug Reactions) study. PREPARE aims to implement pharmacogenomic testing to guide drug and dose selection in seven European countries, thereby personalizing medicine. PREPARE will provide evidence on the effect of pharmacogenomics-based prescribing on patient outcomes. The PREPARE protocol was initiated by the Ubiquitous Pharmacogenomics Consortium (U-PGx). U-PGx is funded by the European Union’s Horizon 2020 grant, and is a project which aims to make effective treatment optimization accessible to every European citizen (www.upgx.eu).</p>
<h3>Therapeutic recommendations</h3>
<p>The therapeutic recommendations in this report are developed by the Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association. The Dutch Pharmacogenetics Working Group formulates the optimal recommendations for each phenotype group based on the available scientific evidence. If this optimal recommendation cannot be followed due to practical restrictions, e.g. therapeutic drug monitoring or a lower dose is not available, the health care professional should consider the next best option.</p>
<p>The recommendations in this report are solely based on the phenotypes that were inferred from the variants assayed by the genotyping test deployed in this study. The recommendations do not take into account any other factors that can influence a patient's phenotype and drug response, such as drug-drug interactions, various health conditions or environmental factors. The absence of a recommendation for a specific drug is not to be equated with the general absence of variants that might influence an individual's response to this drug since the patient might have a rarer variant that is currently not covered by the U-PGx genotyping test.</p>
<p>In the course of U-PGx, the database that contains the annotations and recommendations to generate this report will continuously be updated as new scientific evidence becomes available. Therefore, the information included in this report is dependent on the report generation date.</p>
<h3>Additional information on the recommendation for oral/vaginal contraceptives with estrogens</h3>
<p>The recommendation refers to all estrogen containing hormonal contraceptives for systemic use. This includes, but is not limited to, <em>combination preparations of estrogens</em> (e.g. ethinylestradiol, estradiol) <em>with the following progestogens</em>: Cyproteron, Desogestrel, Dienogest, Drospirenon, Etonogestrel, Gestodeen, Levonorgestrel, Nomegestrol, Norelgestromine, Norethisteron, Norgestimaat.</p>
<h3>Genotyping test</h3>
<p dir="ltr">Nucleic acid variants were detected by fluorescence-based endpoint genotyping using two allele-specific forward and one common reverse primer. Determined alleles were compared to the corresponding reference sequences. Fluorescence signals were analyzed and classified using computer-based method.<br><br> The method applied detects bi- and tri-allelic SNPs (single nucleotide polymorphism), insertions, deletions, and duplications. Assignment of a genotype is based on results at the positions investigated which are listed for each analysis.<br><br> As with any PCR-based method, results of genotyping can be influenced by genomic variants in the primer binding region. This can result in findings divergent from those obtained with alternative methods or with PCR products of the region generated with different primers. The method does not preclude point variations, deletions or duplications in regions of the gene other than those investigated.</p> <p><br> Results of genotyping reported are frequently checked as part of continuing method development. Detected allele combinations are assigned to the most likely genotypes using computer-based methods. To confirm those findings or exclude rare genotype and phenotype classification, genotyping of (both) parents is recommended.</p>
  
</details>
<div class="hidden"><h2>Tested variants</h2></div>
<details class="js-form-wrapper form-wrapper">
  <summary role="button" aria-expanded="false" aria-pressed="false" class="heading-2">Tested variants</summary>
  
  
<table>
<thead><tr>
<th>GENE</th> <th>ALLELE</th> <th>VARIANT</th> <th>CORRESPONDING RS ID</th> </tr></thead>
<tbody>
<tr>
<td><em>CYP2B6</em></td> <td>*6/*9</td> <td>516G&gt;T</td> <td>rs3745274</td> </tr>
<tr>
<td><em>CYP2B6</em></td> <td>*4/*16</td> <td>785A&gt;G</td> <td>rs2279343</td> </tr>
<tr>
<td><em>CYP2B6</em></td> <td>*18</td> <td>983T&gt;C</td> <td>rs28399499</td> </tr>
<tr>
<td><em>CYP2C9</em></td> <td>*2</td> <td>430C&gt;T</td> <td>rs1799853</td> </tr>
<tr>
<td><em>CYP2C9</em></td> <td>*3</td> <td>1075A&gt;C</td> <td>rs1057910</td> </tr>
<tr>
<td><em>CYP2C9</em></td> <td>*5</td> <td>1080C&gt;G</td> <td>rs28371686</td> </tr>
<tr>
<td><em>CYP2C9</em></td> <td>*11</td> <td>1003C&gt;T</td> <td>rs28371685</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*2</td> <td>681G&gt;A</td> <td>rs4244285</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*3</td> <td>636G&gt;A</td> <td>rs4986893</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*4A/B</td> <td>1A&gt;G</td> <td>rs28399504</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*5</td> <td>1297C&gt;T</td> <td>rs56337013</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*6</td> <td>395G&gt;A</td> <td>rs72552267&nbsp;</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*8</td> <td>358T&gt;C</td> <td>rs41291556</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*9</td> <td>431G&gt;A</td> <td>rs17884712</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*10</td> <td>680C&gt;T</td> <td>rs6413438</td> </tr>
<tr>
<td><em>CYP2C19</em></td> <td>*17</td> <td>-806C&gt;T</td> <td>rs12248560</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*xN</td> <td>Gene duplication or multiplication</td> <td>X</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*3</td> <td>2549delA</td> <td>rs35742686</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*4</td> <td>1846G&gt;A</td> <td>rs3892097</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*5</td> <td>Gene deletion</td> <td>X</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*6</td> <td>1707delT</td> <td>rs5030655</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*8</td> <td>1758G&gt;T</td> <td>rs5030865</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*9</td> <td>2615delAAG</td> <td>rs5030656</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*10</td> <td>100C&gt;T</td> <td>rs1065852</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*14A/B</td> <td>1758G&gt;A</td> <td>rs5030865</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*17</td> <td>1023C&gt;T</td> <td>rs28371706</td> </tr>
<tr>
<td><em>CYP2D6</em></td> <td>*41</td> <td>2988G&gt;A</td> <td>rs28371725</td> </tr>
<tr>
<td><em>CYP3A5</em></td> <td>*3</td> <td>6986A&gt;G</td> <td>rs776746</td> </tr>
<tr>
<td><em>CYP3A5</em></td> <td>*6</td> <td>14690G&gt;A</td> <td>rs10264272</td> </tr>
<tr>
<td><em>CYP3A5</em></td> <td>*7</td> <td>27131_27132insT</td> <td>rs41303343</td> </tr>
<tr>
<td><em>DPYD</em></td> <td>*2A</td> <td>IVS14 + 1G&gt;A (1905+1G&gt;A)</td> <td>rs3918290</td> </tr>
<tr>
<td><em>DPYD</em></td> <td>*13</td> <td>1679T&gt;G</td> <td>rs55886062</td> </tr>
<tr>
<td><em>DPYD</em></td> <td>X</td> <td>2846A&gt;T</td> <td>rs67376798</td> </tr>
<tr>
<td><em>DPYD</em></td> <td>X</td> <td>1236G&gt;A</td> <td>rs56038477</td> </tr>
<tr>
<td><em>F5</em></td> <td>X</td> <td>1691G&gt;A</td> <td>rs6025</td> </tr>
<tr>
<td><em>HLA-B</em></td> <td>*5701</td> <td>T&gt;G</td> <td>rs2395029</td> </tr>
<tr>
<td><em>HLA-B</em></td> <td>*1502</td> <td>G&gt;C</td> <td>rs3909184</td> </tr>
<tr>
<td><em>HLA-B</em></td> <td>*1502</td> <td>G&gt;A</td> <td>rs2844682</td> </tr>
<tr>
<td><em>HLA-A</em></td> <td>*3101</td> <td>T&gt;C</td> <td>rs1633021</td> </tr>
<tr>
<td><em>HLA-A</em></td> <td>*3101</td> <td>A&gt;T</td> <td>rs1061235</td> </tr>
<tr>
<td><em>SLCO1B1</em></td> <td>*5/*15/*17</td> <td>521T&gt;C</td> <td>rs4149056</td> </tr>
<tr>
<td><em>TPMT</em></td> <td>*2</td> <td>238G&gt;C</td> <td>rs1800462</td> </tr>
<tr>
<td><em>TPMT</em></td> <td>*3B</td> <td>460G&gt;A</td> <td>rs1800460</td> </tr>
<tr>
<td><em>TPMT</em></td> <td>*3C</td> <td>719A&gt;G</td> <td>rs1142345</td> </tr>
<tr>
<td><em>UGT1A1</em></td> <td>*6</td> <td>211(G&gt;A)</td> <td>rs4148323</td> </tr>
<tr>
<td><em>UGT1A1</em></td> <td>*27</td> <td>686(C&gt;A)</td> <td>rs35350960</td> </tr>
<tr>
<td><em>UGT1A1</em></td> <td>*28/*37</td> <td>A(TA)6TAA&gt;A(TA)7TAA/A(TA)8TAA</td> <td>rs8175347</td> </tr>
<tr>
<td><em>VKORC1</em></td> <td>X</td> <td>1173C&gt;T (C6484T)</td> <td>rs9934438</td> </tr>
</tbody>
</table>
<p>&nbsp;</p>
  
</details>
</div>
<div id="as_segment_safetycard" data-segment-key="safetycard" class="as-segment">
    <span class="data"></span>
</div>


 

</body></html>